Stocks
Nu Skin Enterprises Financial Statements (NUS) |
||||||||||
| Nu Skin Enterprisessmart-lab.ru | % | 2020 | 2021 | 2022 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 11.02.2021 | 16.02.2022 | 31.12.2022 | 16.02.2023 | 15.02.2024 | 08.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 2 582 | 2 696 | 2 226 | 2 226 | 1 969 | 1 775 | |||
| Operating Income, bln rub | 257.6 | 234.0 | 159.3 | 110.8 | 48.3 | 84.0 | ||||
| EBITDA, bln rub | ? | 331.6 | 368.5 | 89.0 | 231.8 | 137.7 | -9.22 | |||
| Net profit, bln rub | ? | 191.4 | 147.3 | 104.8 | 104.8 | 8.60 | -103.2 | |||
| OCF, bln rub | ? | 379.1 | 141.6 | 108.1 | 118.6 | 140.1 | ||||
| CAPEX, bln rub | ? | 63.8 | 68.6 | 59.1 | 58.5 | 49.4 | ||||
| FCF, bln rub | ? | 315.3 | 73.0 | 49.0 | 60.1 | 90.7 | ||||
| Dividend payout, bln rub | 78.4 | 76.3 | 77.0 | 77.6 | 28.2 | |||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 41.0% | 51.8% | 0.00% | 73.5% | 903.1% | -27.3% | ||||
| OPEX, bln rub | 1 666 | 1 735 | 1 435 | 1 435 | 1 289 | 1 171 | ||||
| Cost of production, bln rub | 658.0 | 675.2 | 630.9 | 630.9 | 611.9 | 520.0 | ||||
| R&D, bln rub | 23.3 | 27.2 | 0.000 | 23.3 | 22.6 | 22.6 | ||||
| Interest expenses, bln rub | 13.1 | 11.0 | 0.000 | 21.9 | 0.000 | 20.5 | ||||
| Assets, bln rub | 1 957 | 1 906 | 1 821 | 1 821 | 1 806 | 1 583 | ||||
| Net Assets, bln rub | ? | 894.3 | 912.8 | 897.3 | 897.3 | 822.0 | 706.9 | |||
| Debt, bln rub | 500.4 | 465.0 | 479.0 | 479.0 | 607.3 | 501.8 | ||||
| Cash, bln rub | 423.9 | 354.8 | 278.5 | 278.5 | 267.8 | 227.8 | ||||
| Net debt, bln rub | 76.5 | 110.2 | 200.5 | 200.5 | 339.5 | 274.1 | ||||
| Ordinary share price, rub | 54.6 | 50.8 | 42.2 | 42.2 | 19.4 | 16.9 | ||||
| Number of ordinary shares, mln | 52.3 | 50.2 | 50.0 | 50.0 | 49.7 | 49.7 | ||||
| Market cap, bln rub | 2 857 | 2 547 | 2 108 | 2 108 | 965 | 838 | ||||
| EV, bln rub | ? | 2 933 | 2 658 | 2 309 | 2 309 | 1 305 | 1 112 | |||
| Book value, bln rub | 602 | 629 | 624 | 624 | 486 | 522 | ||||
| EPS, rub | ? | 3.66 | 2.93 | 2.10 | 2.10 | 0.17 | -2.08 | |||
| FCF/share, rub | 6.03 | 1.45 | 0.00 | 0.98 | 1.21 | 1.83 | ||||
| BV/share, rub | 11.5 | 12.5 | 12.5 | 12.5 | 9.77 | 10.5 | ||||
| EBITDA margin, % | ? | 12.8% | 13.7% | 4.00% | 10.4% | 6.99% | -0.52% | |||
| Net margin, % | ? | 7.41% | 5.46% | 4.71% | 4.71% | 0.44% | -5.81% | |||
| FCF yield, % | ? | 11.0% | 2.86% | 0.00% | 2.32% | 6.23% | 10.8% | |||
| ROE, % | ? | 21.4% | 16.1% | 11.7% | 11.7% | 1.05% | -14.6% | |||
| ROA, % | ? | 9.78% | 7.72% | 5.75% | 5.75% | 0.48% | -6.52% | |||
| P/E | ? | 14.9 | 17.3 | 20.1 | 20.1 | 112.3 | -8.12 | |||
| P/FCF | 9.06 | 34.9 | 43.0 | 16.0 | 9.24 | |||||
| P/S | ? | 1.11 | 0.94 | 0.95 | 0.95 | 0.49 | 0.47 | |||
| P/BV | ? | 4.75 | 4.05 | 3.38 | 3.38 | 1.99 | 1.61 | |||
| EV/EBITDA | ? | 8.85 | 7.21 | 25.9 | 9.96 | 9.48 | -120.6 | |||
| Debt/EBITDA | 0.23 | 0.30 | 2.25 | 0.86 | 2.47 | -29.7 | ||||
| R&D/CAPEX, % | 36.5% | 39.6% | 39.5% | 38.6% | 45.8% | |||||
| CAPEX/Revenue, % | 2.47% | 2.55% | 0.00% | 2.65% | 2.97% | 2.78% | ||||
| Nu Skin Enterprises shareholders | ||||||||||
